Lonza announced an expansion of Highly Potent API (HPAPI) capabilities from development to commercial scale manufacturing, including formulation and delivery.
Lonza has industry-leading capability in HPAPI development and manufacturing complemented with particle engineering and specialised finished drug products for oral and parental delivery applications.
The new expansion will add two 4m3-scale, multi-purpose production lines for HPAPI manufacturing, improving Lonza's flexibility in existing production lines, helping in shorter time-to-market and accelerated approval timelines for partners.
Lonza reports that the facility will support the delivery of products from AstraZeneca portfolio under a long-term manufacturing agreement.
The HPAPI capacity expansion is expected to be operational by July 2020.
|Lonza Pharma & Biotech
|Scheduled to be operational by 2020